Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Week 96 resistance analysis in participants receiving bictegravir/lenacapavir in the phase 2 ARTISTRY-1 study.

Antiviral therapy - 1 Aug 2026

Pennetzdorfer Nina, Naik Vidula, Montezuma-Rusca Jairo Mauricio, Sklar Peter, Callebaut Christian, Margot Nicolas A

Abstract excerpt

BackgroundARTISTRY-1 is an ongoing Phase 2/3 study evaluating the safety and efficacy of once-daily oral bictegravir (BIC) + lenacapavir (LEN) in virologically suppressed (VS; HIV-1 RNA <50 copies/mL) participants on complex antiretroviral (ARV) regimens. Here, we report Week 96 extension-phase data after transition to BIC/LEN single-tablet regimen (STR).MethodsParticipants without known integrase strand-transfer...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acetamides
Share to Amides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Heterocyclic Compounds, 3-Ring

Share to Heterocyclic Compounds, 4 or More Rings

Share to Indazoles

Share to Piperazines

Share to Pyridones

Share to Quinolones

Source

Identifiers

PMID: 42627157
DOI: 10.1177/13596535261481194

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Week 96 resistance analysis in participants receiving bictegravir/lenacapavir in the phase 2 ARTISTRY-1 study.PMID 42627157Read ↗

Baseline and week 48 resistance analysis in participants receiving bictegravir + lenacapavir in the phase 2 ARTISTRY-1 study.Semantic proximity Read ↗

Resistance Analyses in Heavily Treatment-Experienced People With HIV Treated With the Novel HIV Capsid Inhibitor Lenacapavir After 2 YearsSemantic proximity Read ↗

Week 48 resistance analysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF versus Atazanavir + Ritonavir + Emtricitabine/Tenofovir DF in HIV-1 infected women (WAVES study GS-US-236-0128).Semantic proximity Read ↗

Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-existing NRTI ResistanceSemantic proximity Read ↗

Reduced efficacy of HIV-1 integrase inhibitors in patients with drug resistance mutations in reverse transcriptaseSemantic proximity Read ↗

Virological failure and resistance emergence during treatment with bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir/lamivudine in people living with HIV without prior resistance mutations: a real-world study.Semantic proximity Read ↗

Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysisSemantic proximity Read ↗

HIV-1 drug resistance in people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysisSemantic proximity Read ↗

Characterization of HIV-1 drug resistance development through week 48 in antiretroviral naive subjects on rilpivirine/emtricitabine/tenofovir DF or efavirenz/emtricitabine/tenofovir DF in the STaR study (GS-US-264-0110).Semantic proximity Read ↗

Short Communication: Dolutegravir-Based Regimens Are Active in Integrase Strand Transfer Inhibitor-Naive Patients with Nucleoside Reverse Transcriptase Inhibitor Resistance.Semantic proximity Read ↗

Dolutegravir versus placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated substitutions: 48-week results from VIKING-4, a randomized study.Semantic proximity Read ↗

96-week resistance analyses of the STaR study: rilpivirine/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive, HIV-1-infected subjects.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.